This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project will evaluate a chemically modified siRNA for the ability to suppress hepatitis C virus (HCV) replication in HCV-infected chimpanzees. The study will be conducted in two phases: pharmacokinetics and efficacy. The pharmacokinetics will be conducted in two non-HCV-infected chimpanzees. Blood samples will be obtained at multiple time points following a single IV inoculation of the compound and various parameters of PK will be determined to optimize the dosing during efficacy. The efficacy will involve testing of the antiviral compound in 2 HCV infected chimpanzees. Animals will receive 4 weekly IV injections with the antiviral formulation. Blood samples will be obtained at multiple times to determine the effect on HCV viral load. The animals will be monitored for blood chemistries and CBC at all bleeds to determine safety in a non-human primate model.
Showing the most recent 10 out of 444 publications